Improving Healthspan and Increasing Lifespan

Redefining What’s Possible in Healthy Longevity

Aging is the single greatest risk factor for chronic diseases—including cancer, Alzheimer’s disease, diabetes, osteoarthritis, macular degeneration, sarcopenia, and many others. Gerotherapeutics aim to address the root biological drivers of aging itself, with the potential to dramatically extend healthspan and reduce the global burden of age‑related disease. A truly effective gerotherapeutic would be transformative—its impact measured not just in years gained, but in millions of healthy, productive life‑years restored.

Eos SENOLYTIX is advancing this vision.

We are a longevity biotechnology company developing novel gerotherapeutics that target the fundamental mechanisms of aging. Our lead candidate, PTC‑2105, is powered by our proprietary MitoXcel™ Technology, a platform designed to precisely target the universal decline in mitochondrial membrane potential (MMP or ΔΨm) that occurs across all cells as they age.

A Single Aging‑Specific Target With System‑Wide Impact

MitoXcel™ geropeptides are engineered to recognize and act on the diminished ΔΨm that characterizes senescent cells and aging cells across all tissues. By engaging this unique and aging‑specific vulnerability, MitoXcel™ geropeptides drive two coordinated rejuvenation mechanisms:

1. Rapid restoration of mitochondrial function—returns the efficiency of mitochondrial function in aging cells almost immediately back to their younger, more efficient phenotype
2. Progressive apoptotic clearance of senescent cells—steadily and profoundly triggers apoptotic self-elimination of senescent cells throughout every organ in the body, including senescent glial cells in the brain, reducing their negative systemic inflammatory effects, with no apparent adverse side effects observed.

By targeting a fundamental process shared across all living organisms, we believe MitoXcel™ Technology opens the door to interventions once considered impossible—targeting aging itself as a modifiable, biological condition to drive clinically meaningful improvements in a broad range of age-associated diseases.

Our Origin and Family of Companies

Founded in 2017 in Houston, Texas, SENOTHERAPEUTIX, Inc. began with a mission to develop true gerotherapeutics capable of improving healthspan and extending lifespan. The Company’s groundbreaking discoveries in geroscience and longevity biotechnology led to the creation of three wholly owned subsidiaries—each applying our core technologies to a different domain of human health.

In 2025, SENOTHERAPEUTIX, Inc. registered the Texas d/b/a GEROTHERAPEUTIX, Inc., and today its innovation pipeline is advanced through:

1. Eos SENOLYTIX – Developing novel MitoXcel™ geropeptide therapeutics aimed at improving healthspan and extending lifespan.
2. Perseus SENOLYTIX – An oncology company creating first‑in‑class MitoXcel™ “oncopeptides,” leveraging the same mitochondrial target to pursue safer, more selective cancer treatments.
3. Phoenix SENOLYTIX – Developing next‑generation, controllable gene therapies using our proprietary ApoptiCIDe™ purposeful cell elimination technology to improve healthspan and increase lifespan.

GEROTHERAPEUTIX is executing on its bold vision to develop the iconic longevity medicine company of our time.  Visit each affiliate company—and the MitoXcel™ Technology site—to learn more about the breakthrough science driving this new era of longevity medicine.